Current diagnosis of depression is based solely on behavioral symptomatology. The available US Food and Drug Administrationapproved treatments for depression have come from serendipitous discovery and are ineffective in nearly 30-50% of patients, which is thought to reflect a lack of specificity in targeting underlying pathophysiological mechanisms. Recent evidence has identified depression-related disruptions in a neuroimmune axis that interfaces the immune system and CNS to control behavior. This Review examines the evidence in patients and in animal models of depression that demonstrates how the peripheral immune system acts on the brain to alter an individual's response to stress, ultimately contributing to their vulnerability to mood disorders.
Depression alters the brain of an individual and has a physical impact on the body. Subsets of patients with major depressive disorder (MDD) have higher levels of several inflammatory markers, including the cytokine interleukin-6 (IL-6) (refs. [1] [2] [3] , along with a greater number of circulating leukocytes 4 . Patients with depression have a higher risk of inflammatory illness such as diabetes, metabolic syndrome and heart disease 5, 6 . Although biological criteria are not at present used to diagnose depression, it is noteworthy that the newest diagnostic criteria for MDD identify inflammation as a possible cause 7 . It is estimated that approximately 30-50% of patients with depression are not responsive to approved antidepressant treatments 8 , and this may reflect disease mechanisms of depression, such as increased inflammation, that are not ubiquitously treated with standard antidepressants. It is also unclear whether inflammation plays a causal role in the development of depression. Here we discuss recent research examining the role of peripheral and central inflammation in depression. We argue that inflammation is a contributing factor to the development of mood disorders and discuss data from human studies and animal models supporting this theory.
The immune system and MDD The original link between inflammation and depression was a result of studies that examined psychiatric complications following longterm treatment with interferon-α for hepatitis C (ref. 9) . A subset of patients with hepatitis C who received chronic interferon treatment went on to develop depression 9, 10 , and some of these patients reported greater physical pain before the start of treatment 10 . There is a great deal of correlational evidence that patients who suffer from depression have elevations in circulating cytokines that are proinflammatory in nature, such as tumor necrosis factor-α (TNF-α) 2 , interleukin-1β (IL-1β) 11 and IL-6 (refs. [1] [2] [3] . Furthermore these patients have elevated levels of leukocytes 4 , which may be the source of these increased inflammatory cytokines 12 . A recent study in humans provided the first evidence that peripheral inflammation predates the occurrence of depression, as children with higher circulating levels of IL-6 at age 9 were at a 10% greater risk of developing MDD by age 18 than the general population or children with low levels of IL-6 (ref. 13) .
These studies and others have led clinical investigators to treat depressed patients with anti-inflammatory agents. A recent trial with infliximab, a monoclonal antibody against TNF-α, was found to be effective for altering mood in depressed patients with high basal levels of inflammation before treatment as indicated by circulating levels of C-reactive protein 14 . Other humanized antibody treatments that are in development for a variety of inflammatory illnesses may also be effective in treating mood disorders. For example, tocilizumab, a humanized antibody to the IL-6 receptor, which is approved by the US Food and Drug Administration as a treatment for Castleman's disease and arthritis 15 , is being considered for the treatment of unipolar and bipolar depression 16 . Ustekinumab, an antibody against interleukin 12/23, has also been shown to decrease symptoms of depression and anxiety in humans treated for psoriasis 17 .
Other studies have examined the effects of anti-inflammatory agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) on depression 18 , and a recent meta-analysis indicated that these treatments decrease symptoms of depression as compared to placebo 19 , with the cyclooxygenase-2 (COX-2) inhibitor celecoxib found to be particularly effective, with few side effects 19 . However, overall studies of other selective and nonselective NSAIDs have been mixed, making it difficult to fully evaluate their efficacy in treating depression 20 . Moreover, the NSAID ibuprofen can even interfere with the bioavailability of selective serotonin reuptake inhibitors 21 , which may further complicate their use in depressed populations.
Much like the data from studies of NSAID efficacy, the evidence regarding anti-inflammatory properties of traditional antidepressants is mixed, with some studies reporting that antidepressants reduce systemic inflammation 22 , some reporting no effect 1, 23 and others finding that antidepressants actually increase inflammatory load 24 . There is a growing literature that suggests ketamine, a new type of antidepressant therapeutic that rapidly mitigates treatment-refractory depression 25 , decreases proinflammatory cytokines such as IL-6 and TNF-α in part via the Toll-like receptor (TLR) 4 family 26 . Taken together, studies in humans present strong evidence that inflammation is altered in a subset of depressed patients and has the potential to be used as a target for MDD treatment. However, it is still not clear from these human studies whether peripheral inflammatory mechanisms cause depression or whether more traditional antidepressants exert their therapeutic effects by regulating inflammatory processes. Recent in vivo studies discussed here using animal models of depression (Box 1 and Table 1 ) provide critical information about the inflammatory mechanisms that are functionally related to the behavioral symptoms of depression and antidepressant responses.
Sensing of stress by peripheral immune cells Peripheral immune cells are traditionally assigned to either the innate or the adaptive immune system and they are largely, but not exclusively, derived from hematopoietic stem cells (HSCs) in bone marrow stores 27 . The innate immune system includes myeloid cells, such as granulocytes, monocytes, macrophages and dendritic cells 28 , and innate lymphocytes 29 , such as natural killer (NK) cells.
Innate immune cells mount rapid and effective responses against microbial or sterile injury using readily available cells equipped with pattern recognition receptors that are activated by pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) 30, 31 , respectively. For example, activation of the pattern recognition TLRs results in a cascade that leads to inflammatory cytokine release, along with antigen presentation and phagocytosis 31 . DAMP molecules in particular are powerful danger signals that can be elicited as a response to both physiological and psychological stressors 30 . The 'danger model' of the immune system proposed by Matzinger in 1994 postulates that the role of the immune system is to protect the body from potential exogenous and endogenous injury rather than to differentiate self from nonself 32 . An extension of this idea is that engagement of the innate immune system is one of the first steps in the fight-or-flight response. It is proposed that DAMPs released from epithelial cells in the body and endothelial cells in the blood brain barrier (BBB) 33 , along with activation of the sympathetic nervous system, trigger the hypothalamic-pituitary-adrenal (HPA) axis as a feedback loop to modulate peripheral inflammation (Fig. 1) . Because immune cells express both adrenergic and glucocorticoid receptors 34, 35 , they are able to directly respond to sympathetic nerve signals and HPA axis activation, as exemplified by the inflammatory reflex, a polysynaptic reflex arc (Fig. 1) that modulates the inflammatory response and contributes to the resolution of inflammation 36, 37 . Dysregulation of this feedback loop through changes in sensitivity of the glucocorticoid
The earliest demonstration of a relationship between inflammation and depression associated behavior comes from studies that examined sickness response to systemic administration of an endotoxin, lipopolysaccharide (LPS) 95 , which causes an induction of proinflammatory cytokine release. In this model, following injection with LPS rodents exhibit decreased self care, social interaction, locomotor activity and feeding over the subsequent 24-h period 108 . However, as the expression of the behavior is directly tied to the inflammatory activation by LPS and subsides following a return to baseline, this is considered sickness behavior rather than a model of depression. The models listed below use various forms of stress exposure to induce similar behaviors that last beyond the application of the stressor. These animal models of depression can result in both acute and lasting changes in immune function.
Chronic mild stress. Experimental animals are exposed to a series of variable stressors for at least 2 weeks 109 . The concept is that mild stressors presented in an unpredictable manner over time induce a depression-like state. Following CMS, animals show anhedonic behaviors, such as decreased sucrose consumption, impairments in natural reward associations (conditioned place preference) and reduced brain reward function 110 . They also show deficits in grooming and sexual behavior, and a proinflammatory immune profile 111 ( Table 1) . Many of these effects can be reversed with chronic but not acute antidepressant exposure, making the model relevant to human antidepressant responses.
Learned helplessness. Subjects are exposed to a controllable or uncontrollable stress, such as foot or tail shock, and the latency to actively escape a subsequent stressor is examined. Failure to escape a subsequent stressor via a shuttle box is considered learned helplessness behavior. Animals that are able to control the stressor will learn the new task and escape the shock, whereas the yoked controls exposed to uncontrollable stressors fail to learn the task. Only approximately 20% of animals that undergo the uncontrollable stress are susceptible and develop learned helplessness, whereas the remaining responders are resilient and do not develop learned helplessness. Susceptible animals display anhedonia and altered cytokine profiles ( Table 1) , such as higher levels of circulating IL-6 (ref. 112) , whereas control animals exposed to controllable stressors or resilient animals do not show these same systemic perturbations. In animals that show helplessness behavior, antidepressant treatment of at least 3-5 days is necessary to reverse the effects 113 .
Repeated social defeat stress. Experimental mice are placed in the home cage of an unfamiliar, larger, aggressive mouse each day for 10 d. The larger mouse quickly establishes dominance through physical interaction 114 . Following RSDS, approximately two-thirds of mice-termed susceptibleexhibit depression-like phenotypes as measured by social avoidance, anhedonia, disruptions of the circadian system, increased activation of proinflammatory immune markers such as IL-6 ( Table 1 ) and metabolic changes. The remaining one-third of animals do not develop depression-like behavioral or physiological changes and are termed resilient. Four weeks of chronic antidepressant treatment are required to reverse social avoidance behavior 115 ; however, such treatment does not reduce IL-6 levels 3 . ↓Active avoidance, ↓Libido, ↓Weight, ↑Sleep disturbance ↑IL1α, ↑IL-1β, ↑IL-6, ↑TNF-α, ↑IL-3, ↑IL-10, ↑IL-13, ↑IL-17A, ↑IL-5, ↑GM-CSF, ↑G-CSF, ↑INF-γ, ↑KC, ↑RANTES, ↑IL-2, ↑MIP-1α, ↑MIP-1β
Repeated social defeat stress ↑Anhedonia, ↑Sleep disturbance, ↑Insulin insensitivity, ↑Cocaine conditioned place preference, ↓Exploratory anxiety, ↓Libido, ↓Weight ↑IL-1β, ↑IL-6, ↑IL-10, ↑KC, ↑MCP1, ↑IL-7, ↑VEGF Box 1 Animal models of mood disorders r e v i e w npg r e v i e w receptors on innate immune cells 38, 39 has been shown to shift the immune system to a stress-sensitive response (see ref. 40 for an indepth review).
In response to both psychological stress and trauma-related injury, neutrophils rapidly increase in number-a process termed reactive granulopoiesis 41 -followed by an increase in monocytes. Immature Ly6C hi monocytes and neutrophils circulate in blood and are recruited to tissues when inflammatory signals are present 42 . In blood, Ly6C hi monocytes also mature into Ly6C lo monocytes, a functionally distinct subset that is thought mainly to survey the integrity of the blood vessel endothelium 42 . Injury signals lead to the release of inflammatory chemokines and cytokines by tissueresident dendritic cells and macrophages that recruit neutrophils and monocytes to the damaged tissues. Infiltrating monocytes can differentiate into macrophages to supplement tissue-resident macrophages and dendritic cells, contributing to the inflammatory process or the resolution of inflammation 42 . When inflammatory cues are presented continuously, their presence creates an important part of a vicious cycle. Hence, inflammatory monocytosis is a hallmark of chronic stress-related pathologies, which are characterized by an exaggerated and sustained inflammatory state in the body that may influence brain circuits to control behaviors relevant to depression and anxiety.
Adaptive immune cells comprise T and B lymphocytes and mount targeted and enhanced responses in secondary lymphoid organs, such as lymph nodes and spleen. Adaptive immune responses are stored as immunological memory in the form of specialized memory cells. Prolonged sympathetic activation restricts T cell mobility by blocking lymphocyte egress from secondary lymphoid organs and suppresses inflammation 43 . It has been speculated that the adaptive immune system may also store immunological memory through these specialized memory cells in the case of chronic stress, thereby inoculating an individual to protect against future stress exposure. Thus, the neuroimmune axis exerts important homeostatic functions and regulates both innate and adaptive immunity in response to stress signals.
Sensing of stress by CNS-resident immune cells
Microglia are the tissue-resident macrophages of the brain 44 . They colonize the rudimentary brain early during embryonic development and self-renew locally throughout the life of the animal in the steady state 45, 46 . Microglia depend on two main cytokines to survive, colony stimulating factor 1 and IL-34, which are produced by distinct neuronal populations in the brain 47, 48 . There is also evidence that dendritic cells, along with other leukocytes and lymphocytes, may enter the healthy brain in small numbers via the circumventricular organs 49 , the choroid plexus 50, 51 and a brain lymphatic system 52 . It has been proposed that the endothelial cells that comprise these areas act as a permissive immunomodulatory 'gate' actively promoting homeostasis 49 and that this permissibility, along with an increase in infiltration, may increase with aging 51 . Once in the brain, these peripheral cells act to support brain plasticity and may even contribute npg r e v i e w to cognitive function 51 . While beyond the scope of this Review, these findings have important implications for cognitive decline associated with normal aging, Alzheimer's disease and depression. While the role of microglia in the healthy adult brain is still under investigation, recent studies have demonstrated that microglia dynamically survey their environment 53 , promote synaptic pruning 54, 55 and can use the chemokine receptor CX3CR1 to detect neuronal damage by sensing the neuron's downregulation of CX3CL1 (ref. 56) . Upon exposure to tissue damage, microglia, like other tissue-resident macrophages, promote the recruitment of blood circulating monocytes for help in mitigating damage 57, 58 . In mice exposed to social defeat stress, monocytes have been shown to infiltrate brain Binding of cytokines to specific receptors on endothelial cell can also induce production and subsequent release of inflammatory mediators into the brain. Finally, if the BBB is weakened and becomes more permeable, monocytes can tunnel through, affecting neighboring astrocytes, which surround blood vessels with their endfeet. Circulating cytokines in the brain activate microglial stress response and may induce persistent synaptic changes.
npg r e v i e w regions specifically associated with depression and anxiety 59 , where they differentiate into microglia-like cells and increase local inflammatory processes 60 (Fig. 2) . Notably, recent research using deep sequencing techniques on microglia and peripheral macrophages has indicated that a number of genes have cell type-specific expression patterns 61 . This analysis elucidated a microglial-specific sensome, leading to an increased understanding of how microglia survey their environment. As animals age, their microglial profiles shift away from inflammatory activation toward a more neuroprotective state that acts to maintain homeostasis. In the case of stress disorders where the periphery continues to be primed for a proinflammatory, potentially neurotoxic state, there may well be cell type-specific transcriptional profiles governing the microglial sensome that contribute to depression onset.
Peripheral immune cells and cytokines in depression
In the early 1990's Maes, Smith and colleagues examined the relationship between the peripheral immune system and depression 4 and put forth a theory suggesting that immune dysregulation contributes to behavioral symptoms of the illness 62, 63 . This was largely based on the observation of increased neutrophils and Ly6C hi monocytes in the blood of patients with MDD. Subsequent work from animal models reported elevation of neutrophils and Ly6C hi monocytes following prolonged periods of stress 4, 64 , and causal links were made between peripheral inflammation and the expression of depressionor anxiety-like behaviors 3, 59 , supporting the theory proposed by Maes and colleagues. Our group has recently demonstrated that differences in the innate peripheral immune system predict susceptibility or resilience to repeated social defeat stress (RSDS) 3 (see Box 1). Before stress exposure, animals that later prove susceptible have higher numbers of circulating monocytes, and they release more IL-6 when their leukocytes are stimulated by lipopolysaccharide (LPS) ex vivo or following acute stress in vivo. To examine whether these individual differences in the peripheral immune system are causal to the development of stress susceptibility, HSCs were removed from stress-susceptible mice releasing high IL-6 or from IL-6 knockout (Il6 −/− ) mice and transplanted into wild-type mice whose peripheral immune cells had been lethally irradiated. Stress-susceptible bone marrow chimeras exhibited increased susceptibility to RSDS whereas Il6 −/− bone marrow chimeric mice, as well as those treated with a systemic IL-6 monoclonal antibody, were resilient to RSDS. These findings were replicated in a purely emotional stressor with no physical component, demonstrating that this is not simply a peripheral response to physical trauma. Taken together, these results suggest that dysregulated innate immune responses can increase stress susceptibility and contribute to the development of depression behaviors.
A recent study reported that transplantation of lymph node cell suspensions from chronically stressed mice into Rag2 knockout mice, which lack mature lymphocytes, was associated with subsequent active coping responses in the unstressed host mice 65 . Thus, it is possible that transplantation and/or differentiation of progenitor cells in the adaptive immune system contribute to behavioral effects opposite to those described above for the innate immune system. Despite the fact that donors exhibited a clear proinflammatory profile following stress, transfusion of these donor-derived lymphocytes into Rag2 knockout mice resulted in a shift toward anti-inflammatory-like responses, suggesting that adaptive immune cells may somehow be reprogrammed by stress to promote resilience. However, the question remains whether the developmental effects of lymphocyte knockout in Rag2 mice is truly representative of what might occur after transfusion of lymphocytes into normally developing wildtype mice or whether this is a reflection of developmental side effects attributable to chronic immunosuppressive profiles in Rag2 knockout mice.
Other studies have shed light on the potential upstream mechanisms behind the inflammatory changes observed in chronic stress. In mice, chronic mild stress (CMS) leads to increased adrenergic innervation of the bone marrow stroma. Norepinephrine release from these adrenergic neurons decreases the expression of HSC quiescence factors produced by bone marrow stromal cells and consequently induces HSC activation and output of neutrophils and monocytes through a β 3 -adrenergic receptor mechanism 64 (Fig. 1) . Also, stress-induced desensitization of the glucocorticoid receptors directly on splenic monocytes 66 can contribute to anxiety-like behavior and increases in circulating cytokines. This occurs in part through a cytokine-mediated mechanism whereby nuclear factor κB is not separated from the glucocorticoid receptor, thereby blocking translocation to the nucleus 67 . In addition, glucocorticoids can act directly on HSCs to balance proliferation and function 68 ; however, further studies are needed to determine whether glucocorticoid-dependent mechanisms, like β 3 -adrenergic receptor mechanisms, regulate HSCs in chronic stress models and depression.
Interface between peripheral immune cells and brain There are many ways that bone marrow-derived leukocytes can alter activation of the brain and affect behavior. Some cytokines, such as IL-6 and IL-1β, can cross the blood-brain barrier via saturable transport 69, 70 to act directly on astrocytes, microglia and neurons throughout the CNS (Fig. 2) , where they act in normal physiological processes such as temperature regulation, neuronal differentiation and survival, astrocyte proliferation and modulation of pain 71 . Monocytes can also traffic to the brain by traversing gaps in the epithelial lining that makes up the BBB 59, 72 . This is particularly interesting in light of recent evidence that stress itself can disrupt the BBB, allowing greater access of peripheral cells to the brain 73 . In elderly patients with mood disorders, there is an altered cerebrospinal fluid to serum albumin ratio indicative of BBB disruption 74 . A recent study conducted on postmortem brains has suggested that more peripheral monocytes are indeed being recruited into the brains of depressed patients than in those of controls not diagnosed with a psychiatric disorder 75 .
In the rodent social defeat model, proinflammatory Ly6C hi monocytes infiltrate brain regions specifically associated with depression and anxiety 59 , after having been lured to these sites by local increases of chemotactic cytokines and adhesion molecules on endothelium 75 ( Fig. 2) . Once inside the brain, infiltrating monocytes differentiate into monocyte-derived microglia-like cells and produce a local inflammatory response directly contributing to anxiety-like behavior 72, 76 . In contrast, bone marrow transplantation of wild-type mice with CCR2-deficient hematopoietic progenitors prevents monocyte trafficking and promotes resilience to social stress 59 . CCR2 has also been implicated in Alzheimer's disease, a neurological condition for which depression and anxiety are highly comorbid 77 . Knockout of Ccr2 in an animal model of Alzheimer's disease blocks the accumulation of monocytederived brain macrophages, which reduces clearance of amyloid plaques and results in early onset of cognitive symptoms and death 78 . Because these studies were performed using whole-body Ccr2 knockouts, it is unclear whether the effects were due to reduced trafficking or other processes. It is also unclear how long infiltrated monocytes actually take up residence in the brain. Studies in a rodent multiple sclerosis model found that they are cleared within 3 months once inflammation is resolved 57 , whereas other methods of introducing npg r e v i e w them into the brain have found longer periods of residency 76 . In the context of depression, we speculate that neurons and resident microglia in brain regions affected by chronic stress will provide continuous stimuli for surrounding glia to allow inflammatory monocytes to enter the affected brain regions.
Blood circulating cytokines and chemokines can also activate the CNS by modulating cell surface receptors on astrocytes and on the brain endothelial cells that form the BBB. Astrocyte endfeet line the BBB, preserving its integrity and acting as a filter 79 . Increases in peripheral cytokines lead to changes in transcriptome profiles of astrocytes that include the upregulation of chemokines, cytokines and growth factors 80, 81 , which can then be released directly into the CNS. There is evidence from human postmortem tissue from depressed subjects, as well as rodent stress models, that astrocytes are reduced in brain regions controlling mood and emotion 82, 83 . It is thought that chronic stress may act to decrease astrocytic volume and branching of processes by altering structural proteins, such as glial fibrillary acidic protein (GFAP), rather than by decreasing the overall number of astrocytes 84 . This loss of complexity in the processes of astrocytes could then lead to decreased coverage of the BBB and increased penetration of peripheral substances directly into the brain.
Peripheral cytokines and hormones can interface on resident microglia in the CNS to affect depression. Postmortem analysis of brain tissue from subjects with depression 85 and those who commit suicide 86 shows increased activation of microglia. A recent positron emission tomography (PET) study in humans shows that there is greater microglial activation in cortical areas that directly correlate with depression severity 87 . In rodent models of depression, microglia isolated from stressed mice release higher levels of IL-1β and IL-6 following ex vivo exposure to LPS 88, 89 . Furthermore, glucocorticoids may prime microglia during times of stress, as glucocorticoid administration 2-24 h before an acute inflammatory challenge increases release of proinflammatory cytokines including TNF-α, IL-1β and IL-6 from microglia 90 .
Cytokines and chemokines, as well as other danger signals can also act directly on neurons to alter plasticity and promote depression-like behaviors. Intracranial infusions of IL-6 (ref. 91) or administration of IL-1β (refs. 92,93) into the hippocampus increases depressionassociated behavior and reduces neurogenesis, whereas infusion of antibodies to IL-1β (ref. 93) or to IL-6 (ref. 91) , or deletion of the gene encoding IL-6 (ref. 94) , blocks the depressive-like effects induced by CMS. Cytokines can act on serotonin neurons through the kynurenine pathway and tryptophan catabolites 95, 96 , as well as directly on glutamatergic neurons in the frontal cortex 97 and hippocampus 98 to alter synaptic plasticity. Danger signals also act directly on nerve cells that express the TLR4 receptor to alter neurogenesis in the hippocampus 99 , a process important for depression and antidepressant responses 100 . Lastly, cytokines and chemokines can activate a microglia-dependent phagocytic process that engulfs and clears excitatory synapses, altering synaptic transmission and behavior 101 . Additional studies are needed to determine exactly how stress-activated cytokines or danger signals alter plasticity in astrocytes, microglia and neurons across a host of stress-responsive brain regions important to depression.
Collectively, these studies suggest that dysregulated immune responses to stress can lead to exaggerated danger signals in the periphery and circulation. These signals access the CNS via active or passive transport and then amplify the initial inflammatory signal that can act directly or indirectly on plasticity mechanisms known to contribute to stress susceptibility and depression-like behavioral phenotypes.
Future directions
It is imperative that we move beyond characterization of correlational relationships between the immune system and mood disorders. Understanding how the immune system functionally contributes to depression is necessary to develop sensitive bioassays and effective therapeutics. We need to explore how cytokines and chemokines, as well as other danger signals, are acting in the brain to move toward reversing or repairing the damage in patients who already experience depression. We also need to investigate the dynamics of the neuroimmune system across the lifespan. The juxtaposition between greater central infiltration by the periphery and the central shift to an anti-inflammatory state that attempts to mitigate damage has important implications for depression and other neurological illnesses, such as Alzheimer's disease. Activation of perivascular macrophages has been implicated as a possible treatment for Alzheimer's disease 102 , and there is growing evidence that a brief disruption of the BBB via repeated scanning ultrasound in a mouse model of Alzheimer's disease leads to plaque clearance by microglia, resulting in improved cognition 103 . Therefore, therapies for depression that decrease permeability of the BBB may be beneficial at one age but detrimental to older patients. By studying the immune system in the context of lifespan, we may be able to better tailor treatments to the individual.
Inflammation is also important to a host of other mental disorders, and understanding which aspects of it are specific to depression will be a key question for bioassay development. For example, homeobox protein 8 (Hoxb8), expressed exclusively on bone marrow-derived brain macrophages, has been implicated in obsessive-compulsive disorder, and the excessive grooming behavior in a Hoxb8 mutant can be rescued by bone marrow transplantation from wild-type mice 104 . By combining these areas of investigation, we may be able to augment current antidepressant treatment or even build personalized therapeutics that stem from a more heterogeneous understanding of mental disorders.
Conclusions
Although there is evidence of differences between the mouse and human immune systems transcriptionally 105 and structurally 106 , rodent studies have aided in our understanding of the role of the immune system in depression. It is promising that many of the effects found in stress models recapitulate the dysregulated immune responses observed in stressed humans 107 or patients with MDD 1, 4 . To translate results obtained in mouse models into effective clinical treatments, it is critical to dissect the molecular determinants of immune dysregulation following stress. Furthermore, for diagnostic and therapeutic purposes, we need to build a better representation of the pro-and anti-inflammatory patterns of cytokine production and release related to stress vulnerability and resilience. By understanding cytokine responses along with their downstream effects on neuronal plasticity, we can begin to determine the feedforward loop of the sympathetic nervous system and HPA axis/immune system/CNS that contributes to the onset and occurrence of depressive episodes across an individual's lifespan. By determining the mechanisms that allow inflammatory cells, cytokines and other danger signals to enter the brain, we can develop new therapeutics to act on specific cell types in the body to block access of peripherally derived inflammatory signals to the brain. 
